UK Markets close in 8 hrs 21 mins
  • FTSE 100

    7,129.21
    0.00 (0.00%)
     
  • FTSE 250

    22,684.84
    0.00 (0.00%)
     
  • AIM

    1,188.74
    0.00 (0.00%)
     
  • GBP/EUR

    1.1751
    -0.0015 (-0.13%)
     
  • GBP/USD

    1.3274
    -0.0028 (-0.2124%)
     
  • BTC-GBP

    42,707.09
    -351.18 (-0.82%)
     
  • CMC Crypto 200

    1,445.63
    +6.75 (+0.47%)
     
  • S&P 500

    4,577.10
    +64.06 (+1.42%)
     
  • DOW

    34,639.79
    +617.75 (+1.82%)
     
  • CRUDE OIL

    67.91
    +1.41 (+2.12%)
     
  • GOLD FUTURES

    1,768.80
    +8.10 (+0.46%)
     
  • NIKKEI 225

    28,029.57
    +276.20 (+1.00%)
     
  • HANG SENG

    23,680.46
    -108.47 (-0.46%)
     
  • DAX

    15,263.11
    -209.56 (-1.35%)
     
  • CAC 40

    6,795.75
    0.00 (0.00%)
     

Marinomed partners with Perrigo to distribute virus-blocking Carragelose nasal spray in Scandinavia and France

·5-min read

DGAP-News: Marinomed Biotech AG / Key word(s): Agreement
27.10.2021 / 07:45
The issuer is solely responsible for the content of this announcement.

Marinomed partners with Perrigo to distribute virus-blocking Carragelose nasal spray in Scandinavia and France

Korneuburg, Austria, 27 October 2021 - Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that Marinomed and Perrigo Company plc (NYSE; TASE: PRGO) signed an agreement for the distribution of the virus blocker Carragelose(R) in Finland, Norway, Sweden and France. Perrigo has launched Carragelose under the trade names Physiomer(R) in Scandinavia and Phytosun Aroms(R) in France in September and October 2021. Carragelose products are already available without prescription over the counter (OTC) in more than 40 countries. Carragelose is highly efficient in preventing infection and viral spread of multiple respiratory viruses.

"We are proud to partner with Perrigo, an exceptionally experienced organization, to further extend the global reach of our virus blocker Carragelose. With the likely resurgence of respiratory diseases in the upcoming cold season, we are satisfied that Carragelose will be available to even more people providing them protection from viral respiratory infections," said Dr. Andreas Grassauer, CEO of Marinomed. "The virus-blocking properties of Carragelose can make an important contribution to improving public health and to support hygiene measures against respiratory viruses."

Anneleen Spooren, Vice President International R&D and Innovation at Perrigo, commented: "Marinomed has shown impressive data on the potential of Carragelose for prevention and self-medication of respiratory infections caused by multiple viruses. Carragelose provides an extremely good fit with our portfolio of effective self-care products. We are happy to now expand our portfolio with this clinically validated virus-blocking[1],[2] and hypertonic product that can provide a fast relief of the symptoms. We are convinced that with Marinomed, we have a strong and reliable science-based partner at our side."

About Carragelose(R):
Carragelose(R) is a sulfated polymer from red seaweed and a unique, broadly active virus-blocking compound. It is known as a gentle, effective, and safe prevention and treatment of various viral respiratory infections. Several clinical and preclinical studies have shown that Carragelose(R) forms a layer on the mucosa that entraps entering viruses, thereby inactivating them, and preventing them from infecting cells. Laboratory and clinical data have shown that Carragelose(R) can also inactivate SARS-CoV-2.[3],[4] Marinomed is the holder of the IP rights and has licensed Carragelose(R) for marketing in Europe, Canada, Australia, and parts of Asia and Latin America. Marinomed's portfolio of Carragelose(R)-containing nasal sprays and oral products can be accessed at https://www.carragelose.com/en/portfolio/launched-products, scientific publications on Carragelose(R) at https://www.carragelose.com/en/publications.

About Marinomed Biotech AG
Marinomed Biotech AG (Korneuburg, Austria) (VSE:MARI) is an Austrian science-based biotech company with globally marketed therapeutics. The company is listed on the Prime Market of the Vienna Stock Exchange. Marinomed focuses on the development of innovative products based on two patent-protected technology platforms. The Marinosolv(R) technology increases the solubility and bioavailability of compounds that are hardly soluble in aqueous formulations. The Carragelose(R) platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and may also reduce the risk of an infection with SARS-CoV-2. Carragelose(R) is used as a virus blocker in nasal sprays, throat sprays, and lozenges, which are sold via international partners in over 40 countries. Marinomed, Marinosolv(R) and Carragelose(R) are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only. Further information is available at https://www.marinomed.com.

For further inquiries contact:

Marinomed Biotech AG
Lucia Mayr-Harting, PR
Hovengasse 25, 2100 Korneuburg, Austria                    
T +43 2262 90300 158
E-mail: pr@marinomed.com
http://www.marinomed.com

International Media and IR Contact
MC Services AG
Dr. Brigitte Keller, Dr. Regina Lutz
T +49 89 210228 0
UK: Shaun Brown
M: +44 7867 515 918
E-mail: marinomed@mc-services.eu

 

Disclaimer
This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.


[1] https://openvirologyjournal.com/VOLUME/14/PAGE/9/
[2] https://www.carragelose.com/en
[3] https://www.dovepress.com/efficacy-of-a-nasal-spray-containing-iota-carrageenan-in-the-postexpos-peer-reviewed-fulltext-article-IJGM
[4] https://www.marinomed.com/en/news/marinomed-biotech-ag-shares-positive-clinical-trial-results-for-iota-carrageenan-nasal-spray-in-the-prevention-of-covid-19-1


27.10.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting